Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Micke

Showing results (51-60 of 165) with videos related to

Pageof 17
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
c-MET as a biomarker in patients with surgically resected non-small cell lung cancerGeorgios Tsakonas, Johan Botling, Patrick Micke, et al.
Frontiers in Oncology|October 5, 2020
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer ModelDiana Spiegelberg, Anja Charlotte Lundgren Mortensen, Kartika Dyah Palupi, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 9, 2015
Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung CarcinomaLena Tran, Johanna S M Mattsson, Björn Nodin, et al.
Cancer Treatment and Research Communications|April 16, 2022
Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancerJohan Isaksson, Leo Wennström, Eva Branden, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2017
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variabilityHans Brunnström, Anna Johansson, Sofia Westbom-Fremer, et al.
Scientific Reports|February 6, 2019
Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancerPatrick Micke, Johan Botling, Johanna Sofia Margareta Mattsson, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 30, 2014
The lung-specific proteome defined by integration of transcriptomics and antibody-based profilingCecilia Lindskog, Linn Fagerberg, Björn Hallström, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survivalSebastian Marwitz, Hans Brunnström, Miklos Gulyas, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2012
Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumorsKarolina Edlund, Ola Larsson, Adam Ameur, et al.
Scientific Reports|November 18, 2021
TGF-β-mediated epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinomaNaoya Miyashita, Takayoshi Enokido, Masafumi Horie, et al.
Pageof 17

Showing results (51-60 of 165) with videos related to

Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
c-MET as a biomarker in patients with surgically resected non-small cell lung cancerGeorgios Tsakonas, Johan Botling, Patrick Micke, et al.
Frontiers in Oncology|October 5, 2020
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer ModelDiana Spiegelberg, Anja Charlotte Lundgren Mortensen, Kartika Dyah Palupi, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 9, 2015
Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung CarcinomaLena Tran, Johanna S M Mattsson, Björn Nodin, et al.
Cancer Treatment and Research Communications|April 16, 2022
Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancerJohan Isaksson, Leo Wennström, Eva Branden, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2017
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variabilityHans Brunnström, Anna Johansson, Sofia Westbom-Fremer, et al.
Scientific Reports|February 6, 2019
Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancerPatrick Micke, Johan Botling, Johanna Sofia Margareta Mattsson, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 30, 2014
The lung-specific proteome defined by integration of transcriptomics and antibody-based profilingCecilia Lindskog, Linn Fagerberg, Björn Hallström, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survivalSebastian Marwitz, Hans Brunnström, Miklos Gulyas, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2012
Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumorsKarolina Edlund, Ola Larsson, Adam Ameur, et al.
Scientific Reports|November 18, 2021
TGF-β-mediated epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinomaNaoya Miyashita, Takayoshi Enokido, Masafumi Horie, et al.
Pageof 17